Phase 2 Readout~quarter

Phase 2 Readout: scy-770

Indication
autosomal dominant polycystic kidney disease

Other upcoming events for SCYX

Phase 2 ReadoutPhase 2 Readout: scy-770
Patent ExpiryPatent/Exclusivity Expiry: BREXAFEMME

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Readout: scy-770 — SCYX Phase 2 Readout | BioSniper